glp-1 uses Agonists: Using Semaglutide, Tirzepatide, and Orforglipron for Weight Loss and Obesity KFF's latest Health Tracking Poll

The lists below describe some of the more common side effects it may cause

Young people deserve a health care system that values our lives, and illicit weight-loss drugs are not part of that

While this slowing often attenuates over time with continued treatment, the effect may persist with long-acting agents and varies between individuals

However, cortical bone thickness was decreased in the semaglutide group ( P = 0.032), while no significant changes in bone microarchitecture or biomechanical strength were noted

this may suggest that these findings are not attributable to weight reduction

Meanwhile, more perimenopausal and early menopausal women are seeking anti-obesity treatments, Kohrt said